menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Epilepsia Publishes FINTEPLA Long-Term Safety Data In Dravet

    PR NEWSWIRE

    FINTEPLA® (Fenfluramine) Results On Managing Seizures Published In Epilepsia

    PR NEWSWIRE

    UCB Launches Dravet Syndrome Sound of Profound Moments: Family Video Project

    BUSINESSWIRE

    Acino completes acquisition of M8 Pharmaceuticals

    GLOBENEWSWIRE

    UCB presents new data about the real-world experience of FINTEPLA

    PR NEWSWIRE

    UCB Announces FINTEPLA® (fenfluramine) Oral Solution

    PR NEWSWIRE

    CHMP recommends fenfluramine for LGS-associated seizures

    EUROPEANPHARMACEUTICALREVIEW

    Epilepsia Publishes Interim Results of Open-Label Extension Study of FINTEPLA

    PRNEWSWIRE

    NICE recommends UCB’s Fintepla for Dravet syndrome

    PHARMATIMES

    Fenfluramine found effective in preventing drop seizures from LGS

    EUROPEANPHARMACEUTICALREVIEW

    JAMA Neurology Publishes PIII Study Results on Efficacy and Safety of FINTEPLA

    PRNEWSWIRE

    UCB takes on Jazz in severe epilepsy with new Fintepla label approval

    PHARMAPHORUM

    Zogenix To Present New Long-term Data on FINTEPLA in Lennox-Gastaut Syndrome

    GLOBENEWSWIRE

    Zogenix Submits Type II Variation Application to (EMA) to the Use of FINTEPLA

    GLOBENEWSWIRE

    Zogenix Submits Supplemental New Drug Application for FINTEPLA®

    GLOBENEWSWIRE

    Zogenix Receives Orphan Drug Designation for FINTEPLA (Fenfluramine) in Japan

    GLOBENEWSWIRE

    Zogenix Launches Global Access Program for FINTEPLA® (Fenfluramine)

    PRESS RELEASE

    Zogenix introduces Fintepla oral solution in Germany for treatment of seizures

    PHARMABIZ

    EU green light for Zogenix’s Fintepla

    PHARMATIMES

    Zogenix gets EU marketing authorisation for anti-seizure drug

    PHARMAFILE

    EU green light for Zogenix’s Fintepla

    RUTERS

    Zogenix gets EU marketing authorisation for anti-seizure drug

    PHARMAFILE

    Zogenix proposes $200M debt offering

    SEEKING ALPHA

    Zogenix`s Fintepla successful in third pivotal study in severe type of epilepsy

    SEEKINGALPHA

    FDA Approvals Roundup: Fintepla, Dojolvi, Phesgo

    RAPS

    FDA Approves New Therapy for Dravet Syndrome

    FDA

    So close, yet so far: Zogenix LGS trial succeeds, but results underwhelm

    ENDPTS

    Zogenix Announces +ve Top-line Results Global Pivotal Ph3 Trial of FINTEPLA®

    PRESS RELEASE

    The Lancet Publishes Ph 3 Trial Results for Zogenix Drug FINTEPLA

    GLOBE NEWSWIRE

    French weight-loss pill scandal set for landmark trial

    REUTERS

    Zogenix data blunder trips up FDA filing for epilepsy drug Fintepla

    FIERCE BIOTECH

    Wall Street darling Zogenix shares positive PhIII data on rival drug

    ENDPTS

    Chasing GW, Zogenix scores a win in second Dravet phase 3

    FIERCE BIOTECH

    Is DEA Being Forced To Reschedule The CBD Compound?

    FORBES

    Zogenix Receives Orphan Drug Designation in the European Union for ZX008 in Lennox Gastaut Syndrome

    FINANCE YAHOO

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.